TransMedics Group Is Maintained at Overweight by Piper Sandler
TransMedics Gr Analyst Ratings
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $180
Analysts Conflicted on These Healthcare Names: TransMedics Group (TMDX), Vertex Pharmaceuticals (VRTX) and Edwards Lifesciences (EW)
Morgan Stanley Maintains TransMedics(TMDX.US) With Hold Rating, Maintains Target Price $153
TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $175
TransMedics Group (TMDX) Buy Rating Affirmed Amid Rising Market Share and Competitive Edge
Baird Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $200
TransMedics Gr Analyst Ratings
Baird Initiates Coverage On TransMedics Gr With Outperform Rating, Announces Price Target of $200
Baird Initiates TransMedics(TMDX.US) With Buy Rating, Announces Target Price $200
TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $175
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Raises Target Price to $180
Oppenheimer Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $200
Oppenheimer Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $200
Needham Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $208
Needham Reiterates Buy on TransMedics Gr, Maintains $208 Price Target
TransMedics Gr Analyst Ratings
Needham Initiates TransMedics(TMDX.US) With Buy Rating, Announces Target Price $208
Needham Initiates TransMedics Group at Buy With $208 Price Target